Clinical trials: Peritoneal Malignant Mesothelioma
Mesothelioma; Peritoneum, Pseudomyxoma Peritonei
Thrombin Generation and Platelet Activation in CRS/HIPEC
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal peroperative chemotherapy (HIPEC), indicated for patients with peritoneal metastases from digestive or gynecological malignancies alike, demonstrates a considerable…
- Conditions
- Mesothelioma; Peritoneum, Pseudomyxoma Peritonei, Peritoneal Carcinomatosis
- Trial name
- NCT03034850
- Testing
- CRS/HIPEC
- Volunteers
- 27 people
- Sponsor
- Ziekenhuis Oost-Limburg
Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
This is a phase 1 dose escalation study to characterize the feasibility, safety and tolerability of MCY-M11 when administered as an intraperitoneal (IP) infusion for 3 weekly doses for women with platinum resistant high grade…
- Conditions
- Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary, Primary Peritoneal Carcinoma
- Trial name
- NCT03608618
- Testing
- MCY-M11, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- MaxCyte, Inc.
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Peritoneal Carcinomatosis, Pseudomyxoma Peritonei
Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
The purpose of this study is to register the follow-up data of patients who, because of a peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC.
- Conditions
- Peritoneal Carcinomatosis, Pseudomyxoma Peritonei, Peritoneal Mesothelioma
- Trial name
- HIPEC (NCT01617382)
- Where
- Belgium
- Volunteers
- 125 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Peritoneal Malignant Mesothelioma
Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma
Patients primary malignant peritoneal mesothelioma (MPM), without extra-abdominal disease, that are not eligible (or willing) to undergo cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can be…
- Trial name
- INTERACT MESO (NCT05449366)
- Testing
- Intraperitoneal Paclitaxel Solution (Ml)
- Where
- Netherlands
- Volunteers
- 7 people
- Sponsor
- Erasmus Medical Center
Peritoneal Carcinomatosis
PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis
Phase Ib trial including investigating the combination of nab-paclitaxel and cisplatin in patients diagnosed with peritoneal carcinomatosis related to pancreatic, oeso-gastric, ovarian cancer or primitive peritoneal mesothelioma.
- Trial name
- Nab-PIPAC (NCT04000906)
- Testing
- Nab paclitaxel, Cisplatin
- Where
- 2 sites in Switzerland
- Volunteers
- 18 people
- Sponsor
- University Hospital, Geneva
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Peritoneal Malignant Mesothelioma
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma.
- Trial name
- NCT05001880
- Testing
- Atezolizumab, Bevacizumab, Biospecimen Collection
- Where
- 41 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Peritoneal Cancer, Pseudomyxoma Peritonei
Phase I Trial HIPEC With Nal-irinotecan
The purpose of this study is to assess the effectiveness and safety of intraperitoneal administration of heated nanoliposomal Irinotecan in cytoreductive surgery (CRS), which is surgery designed to remove as much of the cancer as…
- Conditions
- Peritoneal Cancer, Pseudomyxoma Peritonei, Mucinous Adenocarcinoma, Mucinous Tumor
- Trial name
- NCT04088786
- Testing
- nanoliposomal irinotecan
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Stony Brook University
Carcinoma, Non-Small-Cell Lung, Mesothelioma
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Mesothelioma, Bladder Cancer, Ovarian Cancer
- Trial name
- NCT03023319
- Testing
- Bosutinib, Pemetrexed
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nagla Abdel Karim
Solid Organ Tumors
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
The purpose of this research study is to collect information from patient's medical records that had a test called ChemoFx® ordered and to understand how doctors may have used the results of the ChemoFx® to treat patients with…
- Trial name
- NCT01271959
- Where
- 25 sites in United States
- Volunteers
- 167 people
- Sponsor
- Precision Therapeutics
Mesothelin Positive, Mesothelin-Expressing Tumors
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified)…
- Conditions
- Mesothelin Positive, Mesothelin-Expressing Tumors, Esophageal Adenocarcinoma, Esophageal Adenocarcinomas
- Trial name
- NCT06623396
- Testing
- M28z1XXPD1DNR CAR
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Malignant Pleural or Peritoneal Mesothelioma
Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma
Malignant mesothelioma is an invasive neoplasm that arises from mesothelium that lines several organs. Common primary sites of origin of mesotheliomas are the pleura (malignant pleural mesothelioma: 85%) and peritoneum (malignant…
- Trial name
- TALAMESO (NCT04462809)
- Testing
- Talazoparib
- Volunteers
- 40 people
- Sponsor
- Hospices Civils de Lyon
Mesothelioma
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma
The purposes of this study are to determine: 1. The safety of Pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs. 2.
- Trial name
- NCT00061477
- Testing
- Pemetrexed, Gemcitabine
- Where
- 10 sites in United States
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Mesothelioma, Mesotheliomas Pleural
Immune Microenvironment and Gene Expression Profiling in Mesothelioma
Pleural and peritoneal mesotheliomas (PPM) are rare cancers mostly related to asbestos-exposure, which are characterized by a complex histopathological diagnosis and staging, few therapeutic options and a dismal prognosis.
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung
- Trial name
- Imaging-Meso (NCT06581549)
- Testing
- Translation analysis
- Where
- 10 sites in Italy
- Volunteers
- 125 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Malignant Peritoneal Mesothelioma
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
The purpose of this study is to test the drug erlotinib (erlotinib hydrochloride) in people with malignant peritoneal mesothelioma who have a specific genetic mutation in their cancer.
- Trial name
- NCT01592383
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Chicago
Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
MESOTIP is a randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma In this study, patients in the experimental…
- Trial name
- MESOTIP (NCT03875144)
- Testing
- PIPAC, Cisplatin, Pemetrexed
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Peritoneal Carcinomatosis, Colorectal Cancer
HIPEC for Peritoneal Carcinomatosis
This is a clinical study investigating the new treatment of surgery combined with intraperitoneal mitomycin-C for patients with gastrointestinal cancer that has spread to the peritoneal (abdominal cavity) surface.
- Conditions
- Peritoneal Carcinomatosis, Colorectal Cancer, Appendiceal Cancer, Peritoneal Mesothelioma
- Trial name
- NCT02040142
- Testing
- HIPEC, Mitomycin C
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Albert Einstein College of Medicine
Peritoneum Cancer, Peritoneum Neoplasm
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Multicentric, international, web-based prospective documentation of the indications and results of Pressurized Aerosol Chemotherapy (so-called PIPAC or PITAC) for treating malignant pleural and peritoneal diseases.
- Conditions
- Peritoneum Cancer, Peritoneum Neoplasm, Pleural Cancer, Pleural Effusion
- Trial name
- PIPACRegis (NCT03210298)
- Testing
- PIPAC
- Where
- 16 sites in Argentina, Australia and 11 more
- Volunteers
- 1,000 people
- Sponsor
- Sabine Rhode